Reducing beta-catenin and IDO expression to potentiate immunotherapy
US11813280B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 3, 2019 |
| Grant date | Nov 14, 2023 |
| Priority date | — |
| Expiry date | Sep 1, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y113/11052
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a β-catenin inhibitor, a therapeutically effective amount of an IDO inhibitor, and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a β-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an IDO inhibitor and an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a β-catenin inhibitor, such as a β-catenin nucleic acid inhibitor molecule, in combination with an IDO inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.